Clinical Features, Diagnosis and Treatment of amyloidosis: A Review


amyloid protein
systemic amyloid deposits

How to Cite

Al-Ameen, S., & Mohammed, R. (2024). Clinical Features, Diagnosis and Treatment of amyloidosis: A Review. Journal of Life and Bio Sciences Research , 5(01), 08 - 12.


  • The name Amyloid is derived from the word "Oid", which means semi-starch, which is a protein that transforms into the shape or amyloid state when a distortion or a change occurs in its secondary structure as it becomes insoluble, shaped, and assembled as beta folded sheets. The structure of the amyloid protein can be seen by the electronic microscope as a group of non-branched fibers, with unspecified lengths and cross-sections between (7.5–10) nanometers. Also, the distinguished structure (the folded beta sheets) is clearly seen, and this structure is responsible for the unique pigmentation that is shown by the amyloid proteins with the Congo red stain.


Adams, D., Koike, H., Slama, M., Coelho, T. (2019). Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nature Reviews Neurology, 15(7), 387-404.

Alrouji, M., Al-Kuraishy, H.M., Al-Gareeb, A.I., Alexiou, A., Papadakis, M., Saad, H.M., Batiha, G.E. (2023). The potential role of human islet amyloid polypeptide in type 2 diabetes mellitus and Alzheimer’s diseases. Diabetology & Metabolic Syndrome 15:101.

Ashraf, G.M., Greige, N.H., Khan, T.A., Hassan, I., Tabrez, S., Shakil, S., Sheikh, I.A., Zaidi, S.K., Wali, M.A., Jabir, N.R., Firoz, C.K., Naeem, A., Alhazza, I.M., Damanhouri, G.A., Kamal, M.A. (2014). Protein misfolding and aggregation in Alzheimer’s disease and Type 2 Diabetes Mellitus?. CNS Neurol Disord Drug Targets, 13(7), 1280–1293.

Babburi, S., Ramya, B, Subramanyam, R.V. , Aparna, V., Srivastava G. (2013). Amyloidosis of the tongue-report of a rare case. Journal of Clinical and Diagnostic Research, 7(12), 3094-3095.

Baker, K.R. (2022). Light chain amyloidosis: epidemiology, staging and prognostication. Methodist DeBakey Cardiovascular Journal, 18(2), 27-35.?

Barahona-Correa, J.E., Morales, S.D., Andrade-Pérez, R., Hani, A. (2021). Renal amyloidosis and crohn disease. Ochsner Journal, 21(3), 291-295.?

Bianchi, G., Zhang, Y., Comenzo, R.L. (2021). AL amyloidosis: current chemotherapy and immune therapy treatment strategies: JACC: CardioOncology state-of-the-art review. CardioOncology, 3(4), 467-487.?

Boes, K.M., Durham, A.C. (2020). In: Pathologic basis of veterinary disease . 6 . Zachary JF , editor. St. Louis, MO, USA : Mosby–Elsevier. Chapter 13–Bone marrow, blood cells, and the lymphoid/lymphatic system. 724 – 804.

Buxbaum, J.N., Dispenzieri, A., Eisenberg, D.S., Fändrich, M., Merlini, G., Saraiva, M.J., Westermark, P. (2022). Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid, 29(4), 213-219.

Chen, G.F., Xu, T.H., Yan, Y., Zhou, Y.R., Jiang, Y., Melcher, K., Xu, H.E. (2017). Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacologica Sinica, 38(9), 1205-1235.?

Comenzo, R.L., Zhou, P., Fleisher, M., Clark, B., Teruya-Feldstein, J. (2006). Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood, 107(9), 3489-91.

Esparvarinha, M., Nickho, H., Mohammadi, H., Aghebati-Maleki, L., Abdolalizadeh, J., Majidi, J. (2017). The role of free kappa and lambda light chains in the pathogenesis and treatment of inflammatory diseases. Biomedicine & Pharmacotherapy, 91, 632-644.

Galkin, A.P. , Sysoev, E. I. (2021). Stress response is the main trigger of sporadic amyloidoses. International Journal of Molecular Sciences, 22, 4092- 4106.

Hamilton, J.A., Benson, M.D. (2001). Transthyretin: a review from a structural perspective. Cellular and Molecular Life Sciences, 58, 1491-1521.?

Hemminki, K., Försti, A. (2021). Epidemiology of amyloidosis and genetic pathways to diagnosis and typing. Hemato, 2(3), 429-440.?

Ihne, S., Morbach, C., Sommer, C., Geier, A., Knop, S., Störk, S. (2020). Amyloidosis—the diagnosis and treatment of an underdiagnosed disease. Deutsches Ärzteblatt International, 117(10), 159.?

Ikura, H., Endo, J., Kitakata, H., Moriyama, H., Sano, M., Fukuda, K. (2022). Molecular mechanism of pathogenesis and treatment strategies for AL amyloidosis. International journal of molecular sciences, 23(11), 6336.?

Jin, X., Wang, G., Xu, X., Bai, Y., An, R., Jiang, D. (2020). Coexistence of Crohn’s disease and systemic lupus erythematosus: a case report and literature review. European Journal of Gastroenterology & Hepatology, 32(9), 1256.?

Joshi, T., Ahuja, N. (2023). The prion basis of progressive neurodegenerative disorders. Interdisciplinary Perspectives on Infectious Diseases, 2023, 1-5.

Kyle, R.A. (2001). Amyloidosis: a convoluted story. Br J Haematol, 114(3), 529-38

Lachmann, H.J., Booth, D.R., Booth, S.E., Bybee, A., Gilbertson, J.A., Gillmore, J.D., Pepys, M.B., Hawkins, P.N. (2002). Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med, 6,346(23), 1786-91.

Lachmann, H.J., Goodman, H.J., Gilbertson, J.A., Gallimore, J.R., Sabin, C.A., Gillmore, J.D., Hawkins, P.N. (2007). Natural history and outcome in systemic AA amyloidosis. New England Journal of Medicine, 356(23), 2361-2371.?

Mallus, M.T., Rizzello, V. (2023). Treatment of amyloidosis: present and future. European Heart Journal Supplements, 25(Supplement_B), B99-B103.?

Merlini, G., Bellotti, V. (2003). Molecular mechanisms of amyloidosis. N Engl J Med, 7,349(6), 583-96.

Milani, P., Basset, M., Russo, F., Foli, A., Palladini, G., Merlini, G. (2017). The lung in amyloidosis. European Respiratory Review, 26(145), 1-8.

Morelato, L., Smojver, I., Seiwerth, S., Gabri?, D. (2021). Extremely rare intraoral presentation of localized amyloidosis. Case Reports in Dentistry, 2021, 1-7.

Ow, S.Y., Dunstan, D.E. (2014). A brief overview of amyloids and Alzheimer's disease. Protein Science, 23(10), 1315-1331.?

Perrone, M.A., Aimo, A., Bernardini, S., Clerico, A. (2022). Natriuretic peptides and troponins to predict cardiovascular events in patients undergoing major non-cardiac surgery. Int. J. Environ. Res. Public Health, 19, 5182.

Picken, M.M. (2013). Non-light-chain immunoglobulin amyloidosis: time to expand or refine the spectrum to include light+ heavy chain amyloidosis? Kidney International, 83(3), 353-356.?

Picken, M.M. (2020). The pathology of amyloidosis in classification: a review. Acta haematologica, 143(4), 322-334.?

Race, B., Williams, K., Hughson, A.G., Jansen, C., Parchi, P., Rozemuller, A.J., Chesebro, B. (2018). Familial human prion diseases associated with prion protein mutations Y226X and G131V are transmissible to transgenic mice expressing human prion protein. Acta neuropathologica communications, 6(1), 1-16.?

Ribes, J., Patel, M., Halim, H., Tooze, S., Kloehn, P. (2022). Prion protein conversion at two distinct cellular sites precedes fibrillisation. Version 1 , 20 May,

Salem, A. M., Salem, M., Moustafa, S. (2021). Surgical treatment of subclavian artery aneurysms. Zagazig University Medical Journal, 27(6), 1582-1591.?

Sandstrom, S. A., Lewis, S. L., Dirksen, S. R., Heitkemper, M. M., Bucher, L. (2014). Study guide for medical-surgical nursing: assessment and management of clinical problems. 9th Ed.Elsevier. 1- 477

Scarpioni, R., Ricardi, M., Albertazzi, V., De Amicis, S., Rastelli, F., & Zerbini, L. (2016). Dialysis-related amyloidosis: challenges and solutions. International journal of nephrology and renovascular disease, 9, 319-328.?

Sehar, U., Rawat, P., Reddy, A.P., Kopel, J., Reddy, P.H. (2022). Amyloid beta in aging and Alzheimer’s disease. International Journal of Molecular Sciences, 23(21), 12924.?

Senecal, J.B., Abou-Akl, R., Allevato, P., Mazzetti, I., Hamm, C., Parikh, R., Woldie, I. (2023). Amyloidosis: a case series and review of the literature. Journal of Medical Case Reports, 17(1), 1-9.?

Shankar, V. (2017). Amyloidosis: Part 2: Pathogenesis & Classification. Diseases of Immune System, General Pathology.

Shi, M., Chu, F., Zhu, F., Zhu, J. (2022). Impact of anti-amyloid-? monoclonal antibodies on the pathology and clinical profile of Alzheimer’s disease: a focus on aducanumab and lecanemab. Frontiers in Aging Neuroscience, 14, 870517.?

Sinnige, T. (2022). Molecular mechanisms of amyloid formation in living systems. Chemical Science, 13(24), 7080-7097.

Sipe, J.D., Benson, M.D., Buxbaum, J.N., Ikeda, S., Merlini, G., Saraiva, M.J., et al. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid. 2010 Sep;17(3-4):101-4

Tao, Y., Qiu, X., Ye, F., Liao, Z., & Wu, P. (2023). Amyloidosis of the tongue: a rare case report. Brazilian Journal of Otorhinolaryngology, 89, 101286.?

Tycko, R. (2016). Molecular structure of aggregated amyloid-?: insights from solid-state nuclear magnetic resonance. Cold Spring Harbor Perspectives in Medicine, 6(8).?1-17.

Vaxmana, I., Gertz, M. (2020). When to suspect a diagnosis of amyloidosis. Acta Haematol, 143, 304–311.

Vrana, J.A., Gamez, J.D., Madden, B.J., Theis, J.D., Bergen, H.R., Dogan A. (2009). Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 3,114(24), 4957-9.

Weigel, D., Colot, V. (2012). Epialleles in plant evolution. Genome Biology, 13(10), 1-6.?

Wilkinson, I.B., Raine, T., Wiles, K., Goodhart, A. Hall, C., Neill, H.O. (2017). Oxford Handbook Of Clinical Medicine.10th edition.

Zerdan, M. B., Nasr, L., Khalid, F., Allam, S., Bouferraa, Y., Batool, S., Chaulagain, C.P. (2023). Systemic AL amyloidosis: current approach and future direction. Oncotarget, 14, 384394.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Copyright (c) 2024 Array